These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 16645210)

  • 21. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
    Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
    Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia.
    Delage R; Soiffer RJ; Dear K; Ritz J
    Blood; 1991 Nov; 78(10):2759-67. PubMed ID: 1824268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia.
    Zion M; Ben-Yehuda D; Avraham A; Cohen O; Wetzler M; Melloul D; Ben-Neriah Y
    Proc Natl Acad Sci U S A; 1994 Oct; 91(22):10722-6. PubMed ID: 7938018
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: implications for defining sensitivity in minimal residual disease.
    Ross DM; Watkins DB; Hughes TP; Branford S
    Clin Chem; 2008 Sep; 54(9):1568-71. PubMed ID: 18641042
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia.
    Hochhaus A; Reiter A; Skladny H; Melo JV; Sick C; Berger U; Guo JQ; Arlinghaus RB; Hehlmann R; Goldman JM; Cross NC
    Blood; 1996 Sep; 88(6):2236-40. PubMed ID: 8822944
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.
    Khalil SH; Abu-Amero KK; Al Mohareb F; Chaudhri NA
    Genet Test Mol Biomarkers; 2010 Feb; 14(1):67-74. PubMed ID: 19943786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-time quantification for BCR-ABL transcripts in chronic myeloid leukaemia patients in UKMMC, Malaysia.
    Wong FL; Hamidah NH; Hawa AA; Nurul AN; Leong CF; Saw F; Ainoon O
    Malays J Pathol; 2011 Dec; 33(2):107-12. PubMed ID: 22299211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Applicability of an absolute quantitative procedure to monitor intra-individual bcr/abl transcript kinetics in clinical samples from chronic myelogenous leukemia patients.
    Kreuzer KA; Lass U; Nagel S; Ellerbrok H; Pauli G; Pawlaczyk-Peter B; Siegert W; Huhn D; Schmidt CA
    Int J Cancer; 2000 Jun; 86(5):741-6. PubMed ID: 10797300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic myeloid leukemia may be associated with several bcr-abl transcripts including the acute lymphoid leukemia-type 7 kb transcript.
    Selleri L; von Lindern M; Hermans A; Meijer D; Torelli G; Grosveld G
    Blood; 1990 Mar; 75(5):1146-53. PubMed ID: 2407300
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection and direct sequence identification of BCR-ABL mRNA in Ph+ chronic myeloid leukemia.
    Sooknanan R; Malek L; Wang XH; Siebert T; Keating A
    Exp Hematol; 1993 Dec; 21(13):1719-24. PubMed ID: 8243571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Magnetic Nanoparticles PCR Enzyme-Linked Gene Assay for Quantitative Detection of BCR/ABL Fusion Gene in Chronic Myelogenous Leukemia.
    Manthawornsiri Y; Polpanich D; Yamkamon V; Thiramanas R; Hongeng S; Rerkamnuaychoke B; Jootar S; Tangboriboonrat P; Jangpatarapongsa K
    J Clin Lab Anal; 2016 Sep; 30(5):534-42. PubMed ID: 26667895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The differences and correlations of BCR-ABL transcripts between peripheral blood and bone marrow assays are associated with the molecular responses in the bone marrow for chronic myelogenous leukemia.
    Jiang Q; Zhao XY; Qin YZ; Liu YR; Lai YY; Jiang B; Huang XJ
    Am J Hematol; 2012 Dec; 87(12):1065-9. PubMed ID: 22965919
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular monitoring of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukemia.
    Arpinati M; Tolomelli G; Bochicchio MT; Castagnetti F; Amabile M; Bandini G; Bonifazi F; Stanzani M; Rosti G; Martinelli G; Baccarani M
    Biol Blood Marrow Transplant; 2013 May; 19(5):735-40. PubMed ID: 23333776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation.
    Zhang JG; Lin F; Chase A; Goldman JM; Cross NC
    Blood; 1996 Mar; 87(6):2588-93. PubMed ID: 8630427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Consistent amounts of acute leukemia-associated P190BCR/ABL transcripts are expressed by chronic myelogenous leukemia patients at diagnosis.
    Saglio G; Pane F; Gottardi E; Frigeri F; Buonaiuto MR; Guerrasio A; de Micheli D; Parziale A; Fornaci MN; Martinelli G; Salvatore F
    Blood; 1996 Feb; 87(3):1075-80. PubMed ID: 8562932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias.
    van Rhee F; Hochhaus A; Lin F; Melo JV; Goldman JM; Cross NC
    Blood; 1996 Jun; 87(12):5213-7. PubMed ID: 8652835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BCR/ABL-mediated increased expression of multiple known and novel genes that may contribute to the pathogenesis of chronic myelogenous leukemia.
    Salesse S; Verfaillie CM
    Mol Cancer Ther; 2003 Feb; 2(2):173-82. PubMed ID: 12589034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multiplex PCR for improved detection of typical and atypical BCR-ABL fusion transcripts.
    Burmeister T; Reinhardt R
    Leuk Res; 2008 Apr; 32(4):579-85. PubMed ID: 17928051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan.
    Yoshida C; Fletcher L; Ohashi K; Wakita H; Kumagai T; Shiseki M; Matsuei K; Inokuchi K; Hatta Y; Shirasugi Y; Yamaguchi T; Sakamoto J; Branford S; Sakamaki H
    Int J Clin Oncol; 2012 Dec; 17(6):584-9. PubMed ID: 21986632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.